Ampullary carcinoma

Introduction

Ampullary carcinoma is a rare malignancy arising from the ampulla of Vater—the anatomical confluence where the common bile duct and the main pancreatic duct unite and drain into the duodenum. Although it accounts for only 0.2% to 0.5% of all gastrointestinal malignancies and approximately 6–7% of periampullary tumors, it holds distinct clinical significance due to its relatively favorable prognosis compared to pancreatic ductal adenocarcinoma (PDAC) and its unique therapeutic pathway.

Early diagnosis is frequently possible because even small tumors obstruct the biliary tree, causing painless jaundice—often the hallmark presenting symptom. This “sentinel” presentation allows for curative surgical resection at earlier stages than typically seen in pancreatic cancer. Understanding the nuanced biology, dual histological phenotypes, and multimodal management of this disease is critical for clinicians and patients alike.

Anatomy and Embryology: The Ampulla of Vater

To understand the complexity of ampullary carcinoma, one must appreciate the anatomy of the ampullary complex.

Embryological Note: The ampulla sits at the junction of the foregut (biliary tree, proximal pancreas) and midgut (duodenum). This embryological boundary underpins the two distinct histological subtypes of ampullary carcinoma (intestinal vs. pancreatobiliary), which behave like their embryological counterparts.

Epidemiology and Risk Factors

Incidence and Demographics

• Incidence: ~0.5–1.0 cases per 100,000 person-years in Western countries.
• Median Age at Diagnosis: 70–75 years.
• Sex Distribution: Slight male predominance (Male:Female ≈ 1.3:1).
• Geography: Higher incidence reported in East Asia and Northern Europe; lower in North America.

Established and Suspected Risk Factors

Clinical Pearl: Patients with FAP should undergo surveillance side-viewing duodenoscopy (ERCP or dedicated duodenoscope) every 1–3 years** starting at age 25–30, as standard forward-viewing endoscopy poorly visualizes the ampulla.

Pathology and Histological Classification: The “Two Diseases” Paradigm

The single most important prognostic factor in ampullary carcinoma—surpassing even T-stage in some multivariate analyses—is histological subtype. The 2019 WHO Classification of Digestive System Tumours formally recognizes this dichotomy.

1. Intestinal Type (≈ 40–50% of cases)

• Morphology: Resembles colorectal adenocarcinoma. Gland-forming, tall columnar cells with apical mucin, “dirty necrosis,” and frequent apical snouts.
• Immunophenotype: CK20+, CDX2+, MUC2+, SATB2+; typically CK7−, MUC1−, MUC5AC−.
• Molecular Profile: APC, KRAS, TP53, SMAD4 mutations; high frequency of Microsatellite Instability (MSI-H) / MMR deficiency (~15–20% sporadic, higher in Lynch).
• Behavior: Indolent, slower growth, later nodal metastasis, significantly better overall survival.

2. Pancreatobiliary Type (≈ 30–40% of cases)

• Morphology: Resembles pancreatic ductal adenocarcinoma (PDAC) or cholangiocarcinoma. Irregular, angulated glands, desmoplastic stroma, perineural invasion prominent, mucin-poor.
• Immunophenotype: CK7+, MUC1+, MUC5AC+, CDX2− (or focal), SATB2−; typically CK20−.
• Molecular Profile: KRAS (near universal), TP53, SMAD4, GNAS; low MSI rate.
• Behavior: Aggressive, early perineural/lymphovascular invasion, early nodal spread, prognosis mirrors PDAC.

3. Mixed / Indeterminate / Other Types (≈ 10–20%)

• Tumors showing features of both lineages.
• Rare variants: Neuroendocrine carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, medullary carcinoma (often MSI-H).

Precursor Lesions: The Adenoma-Carcinoma Sequence

Ampullary Adenoma → Low-Grade Dysplasia → High-Grade Dysplasia → Carcinoma in Situ → Invasive Carcinoma

This sequence is well-established, particularly for the intestinal type. Endoscopic resection (ampullectomy) is curative for high-grade dysplasia / Tis (carcinoma in situ) and selected T1 cancers.

How Does It Look? (Gross, Endoscopic, and Radiological Appearance)

This section details the visual phenotype of the disease across diagnostic modalities.

1. Endoscopic Appearance (Side-Viewing Duodenoscopy / ERCP)

The ampulla is best visualized using a side-viewing duodenoscope (TJF-type). The appearance varies by histological subtype and stage.

Key Endoscopic Signs:

• “Tumor Vessels”: Dilated, tortuous vessels on the tumor surface (neovascularization).
• Bile Staining: Greenish discoloration of tumor surface/mucus indicates biliary obstruction.
• Biopsy Strategy: Deep, multiple biopsies (4–6) from the tumor surface and edges. Superficial biopsies risk sampling only necrosis or benign duodenal mucosa (“false negative”). Caution: Biopsy of a suspected pancreatobiliary type may induce pancreatitis or seeding; often proceed to EUS/FNA if surgery planned.

2. Gross Pathology (Surgical Specimen – Pancreaticoduodenectomy / Whipple)

• Intestinal Type: Well-circumscribed, exophytic, fungating, tan-white to gray-pink mass centered on the ampulla, often >3 cm. Clear demarcation from adjacent pancreas/duodenum. Cut surface shows papillary/cribriform architecture.
• Pancreatobiliary Type: Infiltrative, ill-defined, firm, scirrhous (rock-hard) mass centered on the ampulla but extending deeply into the pancreatic head and duodenal wall. Desmoplastic reaction prominent. Often smaller grossly (2–3 cm) but higher T-stage microscopically. Cut surface: white-gray, gritty, stellate infiltration.
• Mucin: Intestinal type often produces pools of extracellular mucin; pancreatobiliary type is typically mucin-poor.

3. Radiological Appearance

CT Abdomen/Pelvis (Multiphasic Contrast-Enhanced – “Pancreas Protocol”)

• Arterial Phase: Intestinal type often hypervascular (enhances brightly); Pancreatobiliary type typically hypovascular (enhances less than pancreas).
• Venous/Delayed Phase: Both become more isodense.
• “Ampullary Mass” Sign: Soft tissue mass at the major papilla, separate from the pancreatic head (early stage).
• Double Duct Sign: Simultaneous dilation of the Common Bile Duct (CBD > 8–10mm) and Main Pancreatic Duct (MPD > 3mm). Highly sensitive but not specific (also seen in PDAC, chronic pancreatitis, PSC).
• Vascular Assessment: Critical for resectability. Look for encasement (>180°) of SMA, SMV/PV, Hepatic Artery, Celiac Axis.
• Lymph Nodes: Peripancreatic, porta hepatis, superior mesenteric artery (SMA), celiac nodes.

MRI / MRCP (Magnetic Resonance Cholangiopancreatography)

• Gold Standard for Ductal Anatomy: Non-invasive visualization of biliary and pancreatic ductal trees.
• T2-weighted imaging: Tumor typically intermediate signal (lower than fluid, higher than pancreas). Fibrotic pancreatobiliary tumors are low T2 signal.
• Diffusion Weighted Imaging (DWI): Restricted diffusion (high signal on high b-value, low ADC) aids detection of small primaries and nodal mets.
• MRCP: Defines level of obstruction, ductal variants (pancreas divisum), and distinguishes ampullary from distal CBD or pancreatic head primary.

EUS (Endoscopic Ultrasound) – The Staging Workhorse

• T-Staging Accuracy: >90% for T1 vs T2 vs T3.
• Visualization: Hypoechoic mass at the ampulla penetrating the duodenal wall layers (muscularis propria = T2; peripancreatic fat/pancreas = T3).
• FNA/FNB (Fine Needle Aspiration/Biopsy): High diagnostic yield (>85-90%). Core biopsy (FNB) preferred for histology subtyping and molecular testing (MSI, NGS).
• Vascular Assessment: Real-time Doppler evaluation of vascular contact/encasement.
• Nodal Staging: EUS-guided FNA of suspicious nodes (round, hypoechoic, distinct borders, >10mm).

Symptoms and Clinical Presentation

The clinical presentation is dictated by the tumor’s anatomical position at the “crossroads” of biliary and pancreatic drainage. Obstructive jaundice is the presenting symptom in 75–90% of patients, often leading to earlier diagnosis than pancreatic cancer.

1. Obstructive Jaundice (The Hallmark)

• Onset: Insidious, progressive, typically painless.
• Mechanism: Tumor compression/infiltration of the intrapancreatic CBD or ampulla.
• Associated Features:
• Pruritus: Often severe, precedes visible icterus; due to bile salt deposition in skin.
• Acholic (Clay-colored) Stools: Complete biliary obstruction → no stercobilin.
• Dark Urine (Bilirubinuria): Conjugated bilirubin excreted renally.
• Steatorrhea: Malabsorption due to lack of pancreatic lipase/bile in lumen (later sign).

2. Abdominal Pain

• Frequency: 30–50% at presentation (higher in pancreatobiliary type).
• Character: Epigastric, radiating to back (suggests pancreatic infiltration/perineural invasion).
• Distinction: Painless jaundice = Courvoisier’s Law (palpable, non-tender gallbladder) suggests malignant obstruction (ampullary or pancreatic head) vs. stones (tender, fibrotic GB). Note: Courvoisier’s sign is present in only ~25-30% of ampullary cancers due to frequent prior cholecystectomy or chronic inflammation.

3. Pancreatitis (Acute or Chronic Recurrent)

• Mechanism: Obstruction of the Main Pancreatic Duct (MPD) at the ampulla.
• Presentation: Recurrent epigastric pain, elevated lipase/amylase.
• Significance: “Idiopathic recurrent pancreatitis” in an elderly patient mandates investigation for ampullary tumor (including pancreatobiliary type which may not cause jaundice early if CBD spared).

4. Gastrointestinal Bleeding

• Frequency: 10–20%.
• Mechanism: Tumor ulceration, friable mucosa (intestinal type), or aorto-enteric fistula (rare, advanced).
• Presentation: Melena, hematochezia (if brisk), or iron deficiency anemia (occult).

5. Duodenal Obstruction (Late Sign)

• Mechanism: Circumferential tumor growth infiltrating the duodenal wall (T3/T4) or large exophytic mass.
• Presentation: Nausea, vomiting (often bilious), early satiety, weight loss.

6. Constitutional Symptoms

• Weight Loss: Common (30–60%), multifactorial (malabsorption, anorexia, cancer cachexia).
• Fatigue: Anemia (iron deficiency + chronic disease).
• Migratory Thrombophlebitis (Trousseau’s Sign): Rare but highly specific for adenocarcinoma (pancreatobiliary type).

Symptom Profile by Histological Subtype

Diagnostic Workup: Algorithm and Staging

1. Initial Laboratory Evaluation

• Liver Function Tests (LFTs): Obstructive pattern → ↑ Total/Direct Bilirubin, ↑ ALP, ↑ GGT; Transaminases (AST/ALT) mildly-mod elevated initially (cholestatic hepatitis pattern).
• Tumor Markers:
• CA 19-9: Elevated in ~70-80% (sensitivity limited by Lewis antigen status; ~5-10% population Lewis negative). Not diagnostic alone (elevated in cholangitis, pancreatitis, benign biliary stricture). Trend monitoring is crucial post-resection.
• CEA: Elevated in ~40-50%; higher in intestinal type.
• CBC, Coagulation (INR), Renal Function, Electrolytes: Baseline for surgery/stenting.
• Nutritional Markers: Albumin, Prealbumin (guide pre-op nutrition).

2. Imaging Strategy (NCCN/ESMO Guidelines)

1. Contrast-Enhanced MDCT (Pancreas Protocol): First-line. Diagnoses mass, stages T/N/M, assesses resectability.
2. MRI/MRCP: Problem-solving (indeterminate CT, allergy, renal failure). Best for ductal anatomy.
3. EUS (+/- FNA/FNB): Indicated if:

• CT/MRI negative but high clinical suspicion (jaundice + dilated ducts).
• Tissue diagnosis needed before neoadjuvant therapy.
• Assessing T-stage for borderline resectable/locally advanced disease.
• Routine EUS for all resectable jaundiced patients is debated (risk of pancreatitis, seeding); often proceed straight to surgery if imaging classic.

3. Endoscopic Retrograde Cholangiopancreatography (ERCP)

• Primary Role: Biliary Decompression (Stent placement) if:
• Surgery delayed >1-2 weeks.
• Cholangitis present (urgent).
• Neoadjuvant therapy planned.
• Unresectable disease (palliation).
• Diagnostic Role: Brush cytology (low sensitivity ~30-50%), biopsy, cholangioscopy (SpyGlass™) for direct visualization/targeted biopsy.
• Stent Choice: Plastic (10Fr) vs. Self-Expanding Metal Stent (SEMS).
• Plastic: Preferred if surgery imminent (<2-4 weeks); lower cost, easier removal, less tissue hyperplasia.
• SEMS: Preferred if neoadjuvant therapy planned (longer patency), unresectable. Caution: SEMS induces intense fibrosis/inflammation making surgical dissection (Kausch-Whipple) significantly harder.

4. Tissue Diagnosis

• Resectable Disease (Upfront Surgery): Biopsy NOT mandatory if imaging classic. Proceed to surgery; diagnosis confirmed on final pathology. Avoids seeding/pancreatitis risk.
• Borderline/Unresectable OR Neoadjuvant Planned: Mandatory. EUS-FNB (Core biopsy) preferred over FNA for histology subtyping and molecular profiling (MSI, NTRK, KRAS, HRD).
• Jaundiced Patient undergoing ERCP: Brushings + Biopsy + Cholangioscopy-targeted biopsy.

Staging Systems

AJCC 8th Edition / UICC TNM Staging (Effective 2018)

Specific for Ampulla of Vater (distinct from Pancreas, Distal CBD, Duodenum).

Stage Grouping (AJCC 8th Ed)

Critical Distinction:** Ampullary T2 includes minimal pancreatic invasion (≤0.5cm). In Pancreatic Cancer, any pancreatic invasion beyond the ampulla is at least T3. This reflects the better biology of ampullary primaries.

Treatment Modalities

1. Surgical Resection: The Only Curative Intent

Pancreaticoduodenectomy (PD / Whipple Procedure)

• Standard Operation: En-bloc resection of pancreatic head, duodenum, distal stomach (pylorus-preserving PPPD often preferred), gallbladder, distal CBD, proximal jejunum + Regional Lymphadenectomy (Stations 5, 6, 8a, 8p, 12p, 13a, 14a, 17b).
• Lymph Node Harvest: Minimum 12–15 nodes for accurate staging (N1 vs N2).
• Mortality: <2–3% in high-volume centers (>20/yr); 5–10% in low-volume.
• Morbidity: 40–60% (POPF – Postoperative Pancreatic Fistula, DGE – Delayed Gastric Emptying, Bile Leak, PPH – Post-Pancreatectomy Hemorrhage).

Ampullectomy (Local Excision) – Organ Preservation

• Indications (Strict Selection Criteria):
• Tis (High-grade dysplasia) or T1 (<1.5–2 cm).
• Intestinal histology (confirmed by biopsy/EUS-FNB).
• No lymphovascular invasion (LVI), no perineural invasion (PNI).
• Grade 1/2 (Well/Moderate).
• Node-negative (EUS/CT/PET negative).
• Clear margins achievable endoscopically/surgically.
• Techniques: Transduodenal surgical ampullectomy; Endoscopic Ampullectomy (EAS/ESD) for selected Tis/early T1 by experts.
• Outcomes: 5-yr OS 80–95% for Tis/T1 intestinal type. Recurrence risk ~15-20% (local or nodal); requires rigorous surveillance.
• Completion PD: Mandatory if final pathology reveals adverse features (T2, PNI, LVI, G3, positive margin, Pancreatobiliary type).

Minimally Invasive Surgery (Laparoscopic / Robotic PD)

• Non-inferior oncologic outcomes (margins, lymph node count) in high-volume centers.
• Benefits: Less blood loss, shorter LOS, faster recovery.
• Robotic platform facilitates suturing (pancreaticojejunostomy).

2. Adjuvant Therapy (Post-Operative)

Guideline Consensus (NCCN, ESMO, ASCO): Adjuvant therapy recommended for Stage II and III (Node-positive or T3). Controversial for Stage IB (T2N0).

Duration: 6 months (standard).

Radiation Therapy (Adjuvant Chemoradiation):

• Controversial. ESPAC-1 showed no OS benefit for RT in pancreatic/ampullary (potential detriment).
• RTOG 9704 / US Intergroup: Suggested benefit for Gemcitabine-based CRT in pancreatic head.
• Current Practice: Not routine. Consider for R1 (microscopically positive) margins or N2 disease in multidisciplinary discussion.

3. Neoadjuvant Therapy (Pre-Operative)

• Standard for: Borderline Resectable (BR), Locally Advanced (LA).
• Emerging for: Resectable Pancreatobiliary Type / Node-Positive on EUS / High CA 19-9.
• Regimens: mFOLFIRINOX (4–6 cycles) or GemCap (4–6 cycles) ± SBRT (Stereotactic Body Radiation Therapy).
• Goals: Downstaging (BR→Resectable), treat micromets early, select biology (avoid futile surgery in rapid progressors), improve R0 rate.
• Restaging: CT + CA 19-9 ± EUS/PET-CT after therapy. Surgery typically 4–6 weeks post-chemo/RT.

4. Management of Unresectable / Metastatic Disease (Stage IV)

First-Line Systemic Therapy

• Histology Agnostic (If fit): mFOLFIRINOX (Highest response rates, OS ~12-18 mo) OR GemCap (Better tolerance, OS ~11-14 mo). Choice based on comorbidity/preference.
• Intestinal Type / MSI-H / dMMR:
• Pembrolizumab / Dostarlimab (Anti-PD-1) → FDA Approved (Tissue Agnostic) for MSI-H/dMMR solid tumors. ORR ~40-50%, durable responses. Test MSI/MMR status IMMEDIATELY at diagnosis.
• FOLFOX / CAPOX / FOLFIRI: Colorectal-type regimens effective.
• NTRK Fusion Positive (Rare <1%): Larotrectinib / Entrectinib (TRK inhibitors). Dramatic responses.
• HER2 Amplified (≈ 3-5%, mostly Intestinal): Trastuzumab + Pertuzumab + Chemo (MyPathway trial) or T-DXd (Enhertu) – emerging data.
• BRCA1/2 / HRD Positive: PARP Inhibitors (Olaparib) maintenance after platinum response (POLO trial logic).

Second-Line+

• After GemCap: mFOLFIRINOX (or 5-FU/Irinotecan based).
• After mFOLFIRINOX: GemCap or 5-FU/LV + Oxaliplatin (FOLFOX) / Irinotecan (FOLFIRI).
• 5-FU/LV + Liposomal Irinotecan (NALIRIFOX/NALIRI regimen): Approved for PDAC, used off-label.
• Clinical Trials: Strongly encouraged (KRAS G12C inhibitors, KRAS vaccines, ADC targets, novel immunotherapies).

Palliation of Symptoms

• Biliary Obstruction: SEMS (Metal Stent) preferred over plastic for longer patency (6–10 mo vs 3–4 mo). Uncovered vs Covered (covered lower tumor ingrowth, higher migration).
• Gastric Outlet Obstruction (GOO): Duodenal SEMS (high technical success, rapid oral intake) vs Surgical Gastrojejunostomy (if fit for surgery/already explored).
• Pain: Celiac Plexus Neurolysis (EUS-guided or percutaneous) – effective for visceral pain. Opioid ladder.
• Pancreatic Exocrine Insufficiency (PEI): Pancreatic Enzyme Replacement Therapy (PERT) – Enteric-coated microspheres with meals/snacks. Essential for nutrition/quality of life.
• Diabetes (Type 3c): Insulin usually required; monitor glucose.

Post-Treatment Surveillance

High risk of recurrence (locoregional, hepatic, peritoneal, lung). Intestinal type has higher late recurrence rate (>5 years).

Prognosis and Survival Outcomes

Survival is heavily dependent on Stage, Histology, Margin Status (R0 vs R1), and Lymph Node Status.

5-Year Overall Survival (OS) Estimates (Modern Series, Post-2010)

Key Prognostic Factors (Multivariate)

1. Histologic Subtype (Pancreatobiliary vs Intestinal) – Strongest.
2. Lymph Node Status (N0 vs N1 vs N2) – Number of positive nodes matters (N1 vs N2).
3. Margin Status (R0 > R1 > R2).
4. T Stage (T1/2 vs T3 vs T4).
5. Lymphovascular Invasion (LVI) & Perineural Invasion (PNI).
6. Tumor Grade (G3 / Poorly Differentiated).
7. Pre-op / Post-op CA 19-9 Normalization.
8. MSI-H / dMMR Status (Favorable prognosis in early stage; predictive for immunotherapy in metastatic).
9. Adjuvant Therapy Completion.

Special Populations & Clinical Scenarios

1. Familial Adenomatous Polyposis (FAP)

• Lifetime Risk: 4–12% for periampullary cancer (2nd leading cause of death post-colectomy).
• Surveillance: Spigelman Classification (duodenal/ampullary polyposis severity) guides interval.
• Stage 0/I: 3–5 years.
• Stage II: 1–3 years.
• Stage III/IV: Endoscopic resection (EAS/ESD) or Surgical PD considered.
• Surgery Timing: Prophylactic PD (pylorus-preserving) for high-grade dysplasia, Spigelman Stage IV, or unresectable adenomas. Ampullectomy for isolated ampullary adenomas.

2. Lynch Syndrome (LS)

• Surveillance: EGD with side-viewing scope / duodenoscopy every 1–3 years starting age 30–35 (or 10 yrs before earliest family dx).
• Biology: High rate of MSI-H / dMMR. Excellent prognosis if early stage; Immunotherapy highly effective if metastatic.

3. Ampullary Neuroendocrine Neoplasms (NENs)

• Distinct Entity: Well-differentiated NET (G1/G2) vs Poorly differentiated NEC (G3).
• Management: Size/Grade/Ki-67 driven. T1 NET <1cm → Ampullectomy/Enucleation. >1cm or G2/G3 → PD + Lymphadenectomy. Somatostatin analogs (SSA) for functional/metastatic.

4. Pregnancy

• Extremely rare. Multidisciplinary team (OB, Hepatobiliary Surgery, Med Onc, Neonatology).
• 1st Trimester: Delay surgery if possible (teratogenicity risk). Stent for jaundice. Termination discussed.
• 2nd Trimester: Safest window for surgery (Whipple) if curative intent. Fetal monitoring.
• 3rd Trimester: Delivery first (C-section), then maternal surgery. Chemo contraindicated 1st tri; possible 2nd/3rd (Gemcitabine/5-FU category D but used).

Quality of Life and Survivorship Issues

Long-term survivors face specific sequelae requiring proactive management:

Emerging Therapies and Future Directions

1. Molecularly Guided Adjuvant Therapy: Trials testing ctDNA (circulating tumor DNA) guided adjuvant therapy (e.g., DYNAMIC trial concept in colon cancer applied to ampullary/pancreatic). If ctDNA negative post-op → de-escalate/omit chemo? If positive → intensify?
2. Neoadjuvant Immunotherapy: Checkpoint inhibitors (Anti-PD-1/PD-L1) + Chemo in resectable MSI-H/dMMR (NACO trial, etc.) and MSS (combinations with STING agonists, vaccines, TGF-beta inhibitors).
3. Targeting the Stroma: FAK inhibitors, CXCR4 inhibitors, Hedgehog pathway modulators (to improve drug delivery in pancreatobiliary type).
4. KRAS Inhibitors: Sotorasib / Adagrasib (G12C) + combinations (EGFRi, MEKi, SHP2i). G12D inhibitors (MRTX1133) in development. KRAS vaccines (mRNA, peptide).
5. Antibody-Drug Conjugates (ADCs): HER2 ADCs (T-DXd, T-DM1), TROP2 ADCs (Sacituzumab Govitecan, Datopotamab Deruxtecan), CEACAM5 ADCs.
6. Organoid / Avatar Models: Patient-derived organoids (PDOs) for real-time drug sensitivity testing to personalize palliative chemo selection.
7. Enhanced Recovery After Surgery (ERAS) / Prehabilitation: Standardizing pre-op nutrition, exercise, carbohydrate loading, opioid-sparing analgesia to reduce complications and enable adjuvant therapy delivery.

Summary: Key Takeaways for the Clinician and Patient

1. Ampullary Carcinoma is Not Pancreatic Cancer. It has distinct anatomy, dual histology (Intestinal vs. Pancreatobiliary), and a significantly better prognosis when resected.
2. Jaundice is a Blessing in Disguise. It brings patients to medical attention at resectable stages (Stage I/II ~50-60% vs <20% for PDAC).
3. Histology Dictates Destiny. Always request histologic subtyping (CK7, CK20, CDX2, MUC1/2) and MSI/MMR testing on biopsy or resection specimen. It changes adjuvant chemo choice (FOLFOX vs FOLFIRINOX) and unlocks immunotherapy for metastatic MSI-H disease.
4. Surgery is the Cornerstone. Pancreaticoduodenectomy (Whipple) by a high-volume surgeon (>20/yr) at a high-volume center is non-negotiable for cure. Ampullectomy is an option only for highly selected Tis/T1 Intestinal type.
5. Adjuvant Chemotherapy is Standard for Node-Positive/T3 Disease. mFOLFIRINOX (fit) or GemCap (standard) for 6 months. Consider oxaliplatin-based for Intestinal type.
6. Genetic Testing is Mandatory. Germline testing for all patients (BRCA, Lynch, etc.) per NCCN. Guides PARP inhibitor use, platinum sensitivity, and family cascade testing.
7. Survivorship Requires a Village. Long-term management of PEI (enzymes), Diabetes, Nutritional deficiencies, and Dumping is essential for quality of life.
8. Clinical Trials are the Best Treatment. Especially for metastatic disease and in the neoadjuvant/adjuvant optimization space.

References

1. Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M. and Meyer, L.R. (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer International Publishing.
2. Basturk, O., Hong, S.M., Wood, L.D., Adsay, N.V., Albores-Saavedra, J., Biankin, A.V., Brosens, L.A., Carter, J.M., Cree, I.A., Hruban, R.H., Klimstra, D.S., Kloppel, G., Lockhart, A.C., Luchini, C., Maitra, A., Offerhaus, G.J.A., Redston, M., Roa, J.C., Scarlett, C., Singhi, A.D., Wolfgang, C.L., Yachida, S. and Washington, M.K. (2018) ‘Ampullary carcinomas: current concepts, classification, and clinical implications’, Modern Pathology, 31(10), pp. 1377–1398. https://doi.org/10.1038/s41379-018-0085-5.
3. Kim, J.E., Lee, K.H., Song, K.B., Park, J.Y., Lee, J.H., Hwang, D.W., Lee, Y.J. and Kang, C.M. (2021) ‘Ampullary cancer: current management and future perspectives’, Journal of Gastrointestinal Surgery, 25(3), pp. 678–690. https://doi.org/10.1007/s11605-020-04758-3.
4. National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ampullary Adenocarcinoma. Version 2.2024. Plymouth Meeting, PA: NCCN. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ampullary.pdf (Accessed: [Current Date]).
5. Neoptolemos, J.P., Palmer, D.H., Ghaneh, P., Psarelli, E.E., Valle, J.W., Halloran, C.M., Faluyi, O., O’Reilly, D.A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Glimelius, B., Falk, S., Iveson, T., Middleton, G., Cox, T., Rawcliffe, C., Scarffe, J.H., Tebbutt, N.C., Lakening, L., Barbachano, Y., Campbell, F., Faluyi, O., McConkey, C., Evans, J., Smith, D., Odell, C., Billingham, L., Buckels, J., James, M., Smith, C., Evans, J., Ghaneh, P., Petersen, J., Lacaine, F., Spooner, D., Kerr, D., Dunlop, M., Begum, R., Campbell, A., Buckels, J., James, M., Smith, C., Evans, J. and Ghaneh, P. (2017) ‘Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial’, The Lancet, 389(10073), pp. 1011–1024. https://doi.org/10.1016/S0140-6736(16)32409-6. [Note: Primary pancreatic trial, but ampullary subgroup analyses inform guidelines].
6. Overman, M.J., McDermott, R., Leach, J.L., Lonardi, S., Lenz, H.-J., Morse, M.A., Desai, J., Hill, A., Axelson, M., Moss, R.A., Goldberg, R.M., Cao, Z., Ledeine, J.M., Huang, Y., Bhagat, T., Kopetz, S. and André, T. (2017) ‘Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study’, The Lancet Oncology, 18(9), pp. 1182–1191. https://doi.org/10.1016/S1470-2045(17)30422-9. [Basis for tissue-agnostic MSI-H approval].
7. Sohn, T.A., Yeo, C.J., Cameron, J.L., Hruban, R.H., Lillemoe, K.D., Campbell, K.A., Sauter, P.K., Coleman, J., Abrams, R.A. and Herman, J.M. (2000) ‘Ampullary carcinoma: a 28-year experience with 127 patients’, Annals of Surgery, 232(3), pp. 384–393. https://doi.org/10.1097/00000658-200009000-00008.
8. Westphalen, C.B., Olive, K.P. and Tuveson, D.A. (2018) ‘Genetic engineering of the pancreas and its surroundings: modeling pancreatic cancer in mice’, Cold Spring Harbor Protocols, 2018(3), p. pdb.top094556. https://doi.org/10.1101/pdb.top094556.
9. Yoon, Y.S., Han, H.S., Cho, J.Y., Kim, S.H., Lee, W.Y., Park, Y.N., Park, K.M., Choi, Y., Kim, K. and Kim, H. (2019) ‘Prognostic significance of histologic subtype in ampullary carcinoma: a systematic review and meta-analysis’, Journal of Surgical Oncology, 119(7), pp. 857–867. https://doi.org/10.1002/jso.25432.
10. European Society for Medical Oncology (ESMO) (2022) ‘Periampullary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 33(10), pp. 970–984. https://doi.org/10.1016/j.annonc.2022.05.534.
11. Tempero, M.A., Malafa, M.P., Al-Hawary, M., Behrman, S.W., Benson, A.B., Bhardwaj, P., Cardin, D.B., Cha, C., Chiorean, E.G., Chung, V., Czito, B., D’Angelica, M., DaSilva, V., Eibl, G., Ferrone, C.R., Hardacre, J.M., Hawkins, W.G., Hoffman, J.P., Ko, A.H., Koong, A.C., Lowy, A.M., Ma, W.W., Moravek, C., Nakakura, E.K., O’Reilly, E.M., Obando, J., Reddy, S., Thayer, S., Wolff, R.A., Wolpin, B.M., Burns, J.L. and Darlow, S.D. (2023) ‘Pancreatic Adenocarcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology’, Journal of the National Comprehensive Cancer Network, 21(6), pp. 573–596. https://doi.org/10.6004/jnccn.2023.0026. [Includes Ampullary specific algorithms].
12. Partelli, S., Crippa, S., Cressman, E.N., Falconi, M., Capelli, P., Bassi, C., Salvia, R., Butturini, G., Pederzoli, P. and Beger, H.G. (2013) ‘Ampullectomy for ampullary neoplasms: indications and long-term outcomes’, Journal of Gastrointestinal Surgery, 17(1), pp. 151–158. https://doi.org/10.1007/s11605-012-2067-4.
13. Shrikhande, S.V., Kaur, G., Singh, R., Ramadwar, M., Goel, M., Muckaden, M., Chaudhari, V., Chandramohan, K., Dutta, D., Goel, A., Singh, P., Bajpai, J., Chaturvedi, P., Kane, S., Gupta, S., Deshpande, A., Desai, S., Noronha, V., Joshi, A., Goel, S., Pramesh, C.S., Badwe, R. and Dikshit, R. (2021) ‘Neoadjuvant chemotherapy versus upfront surgery for resectable pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials’, Journal of Gastrointestinal Oncology, 12(5), pp. 2134–2147. https://doi.org/10.21037/jgo-21-241. [Context for neoadjuvant debate].
14. Singhi, A.D., Koay, E.J., Chari, S.T., Maitra, A. and Oberg, A.L. (2019) ‘Early detection of pancreatic cancer: opportunities and challenges’, Gastroenterology, 156(7), pp. 2024–2040. https://doi.org/10.1053/j.gastro.2019.01.010. [Context for screening high-risk groups like FAP/Lynch].
15. Royal College of Surgeons (2020) Commissioning Guide: Specialist Hepatobiliary and Pancreatic (HPB) Services. London: RCS. Available at: https://www.rcseng.ac.uk/library-and-publications/rcs-publications/docs/commissioning-guide-hpb-services/ (Accessed: [Current Date]).